News · 26 weeks32+100%
2026-03-012026-08-23
Mix1090d
- Other4(40%)
- Insider3(30%)
- SEC Filings2(20%)
- Dividends1(10%)
Latest news
25 items- INSIDERChief Accounting Officer Zhen Marianne covered exercise/tax liability with 1,127 shares, decreasing direct ownership by 2% to 56,389 units (SEC Form 4) to satisfy withholding obligation4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Executive Officer Raifeld Pavel covered exercise/tax liability with 1,130 shares, decreasing direct ownership by 0.40% to 284,799 units (SEC Form 4) to satisfy withholding tax4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Financial Officer Basso Stephen covered exercise/tax liability with 558 shares, decreasing direct ownership by 0.63% to 88,013 units (SEC Form 4) to cover withholding tax4 - Innoviva, Inc. (0001080014) (Issuer)
- PRInnoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product AwardInnoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced today that three of the company’s infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics product has been recognized by the renowned Galien Foundation. "This is the broadest slate of IST products to be designated as Prix Galien finalists, which is a testament to the clinical significance of the IST portfolio," said Pavel Ra
- SECSEC Form 10-Q filed by Innoviva Inc.10-Q - Innoviva, Inc. (0001080014) (Filer)
- SECInnoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Innoviva, Inc. (0001080014) (Filer)
- PRInnoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company ProgressIST achieved U.S. net product sales of $36.6 million in the second quarter, representing 26% year-over-year growth Royalties portfolio generated $59.8 million in second quarter revenue Launch of wholly-owned Strategic Healthcare Asset, Nortiva Bio, focused on novel extended-release drug delivery technology Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2026, and hi
- PRNortiva Bio Launches to Develop Long-Acting Oral MedicinesCompany is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that last for up to a month, including a monthly oral contraceptive Company seeks pipeline expansion via industry partnerships Nortiva Bio, Inc. ("Nortiva") today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively impact patients' qu
- PRInnoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International MarketsAgreement expands access to XACDURO® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals) The rate of carbapenem resistant -Acinetobacter in these geographies exceeds 70%1,2 representing substantial unmet need Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ:INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® (sulbactam for i
- PRInnoviva to Participate in Upcoming Investor ConferencesInnoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Format: Fireside chat Date: Monday, June 8, 2026 Time: 1:20 p.m. Eastern Time BTIG Infectious Disease Day Format: 1x1 meetings Date: Tuesday, June 16, 2026 A live webcast of the Goldman Sachs fireside chat can be accessed under "Ev
- INSIDERChief Executive Officer Raifeld Pavel covered exercise/tax liability with 1,130 shares and was granted 1,123 shares, decreasing direct ownership by 0.00% to 285,929 units (SEC Form 4) to satisfy withholding tax4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Financial Officer Basso Stephen was granted 1,123 shares and covered exercise/tax liability with 559 shares, increasing direct ownership by 0.64% to 88,571 units (SEC Form 4) to satisfy withholding tax4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Accounting Officer Zhen Marianne covered exercise/tax liability with 1,127 shares, decreasing direct ownership by 2% to 57,516 units (SEC Form 4) (for withholding tax)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERDirector Linden Josephine was granted 15,194 shares (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERNew insider Linden Josephine claimed no ownership of stock in the company (SEC Form 3)3 - Innoviva, Inc. (0001080014) (Issuer)
- SECSEC Form 8-K filed by Innoviva Inc.8-K - Innoviva, Inc. (0001080014) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Innoviva Inc.SCHEDULE 13D/A - Innoviva, Inc. (0001080014) (Filed by)
- SECSEC Form 10-Q filed by Innoviva Inc.10-Q - Innoviva, Inc. (0001080014) (Filer)
- SECInnoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Innoviva, Inc. (0001080014) (Filer)
- INSIDERDirector Dipaolo Mark was granted 9,786 shares, increasing direct ownership by 7% to 140,492 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Executive Officer Raifeld Pavel was granted 126,646 shares, increasing direct ownership by 80% to 285,936 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Accounting Officer Zhen Marianne was granted 12,766 shares, increasing direct ownership by 28% to 58,643 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERChief Financial Officer Basso Stephen was granted 37,994 shares, increasing direct ownership by 76% to 88,007 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERDirector Schlesinger Sarah J. was granted 9,786 shares, increasing direct ownership by 7% to 140,492 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
- INSIDERDirector Small Derek A was granted 9,786 shares, increasing direct ownership by 28% to 45,035 units (SEC Form 4)4 - Innoviva, Inc. (0001080014) (Issuer)
INVA FAQ
7 questionsWhat does Innoviva Inc. do?
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with...Where does INVA stock trade?
Innoviva Inc. (INVA) is listed on NASDAQ.What sector and industry is INVA in?
Innoviva Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Innoviva Inc. go public?
Innoviva Inc. (INVA) completed its IPO in 2004.What are analysts saying about INVA?
Innoviva Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $3500.00 price target on 2026-02-17. Recent price targets range from $1600.00 to $4500.00.What companies are similar to INVA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare INVA side-by-side with any of them on Quantisnow.How can I track INVA on Quantisnow?
Quantisnow aggregates Innoviva Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INVA to receive live email and push alerts on every new disclosure.